Skip to Content

Capricor Therapeutics, Inc.

Securities Class Action

  • Date:
  • 7/29/2026
  • Company Name:
  • Capricor Therapeutics, Inc.
  • Stock Symbol:
  • CAPR
  • Status:
  • Investigating
  • Filing Date:
  • 7/17/2025
  • Court:
  • U.S. District Court: District of Southern California

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:CAPR) on behalf of Capricor stockholders. Our investigation concerns whether Capricor has violated the federal securities laws and/or engaged in other unlawful business practices.

On July 27, 2026, STAT News reported that: “The Food and Drug Administration said Monday that Capricor Therapeutics’ stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of a Phase 3 trial — contrary to the company’s claims last year.” Following this news, the price of the Company’s stock dropped $12.70 per share, or approximately 64.5%, to close at $7.00 per share.

If you purchased or otherwise acquired Capricor shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunatoby email at investigations@bespc.com with any questions regarding the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Capricor Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: